## **Core Concept**
The presence of estrogen receptors (ER+) in breast cancer indicates that the tumor's growth is influenced by estrogen. Estrogen receptor-positive (ER+) breast cancers have receptors that bind to the hormone estrogen, which can promote the growth of cancer cells. This is a critical factor in determining the prognosis and treatment plan for breast cancer patients.

## **Why the Correct Answer is Right**
The correct answer, , implies that the patient with ER+ breast cancer should be informed about the potential benefits of hormonal therapy, such as tamoxifen or aromatase inhibitors, which block the effects of estrogen on cancer cells or reduce estrogen levels in the body. This information is crucial because ER+ tumors are more likely to respond to hormonal therapy, which can significantly improve outcomes for these patients.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not provide specific information related to ER+ status and its implications for treatment or prognosis.
- **Option B:** This option is incorrect as it does not directly relate to the implications of ER+ status in breast cancer.
- **Option D:** This option is incorrect because it does not accurately reflect the significance of ER+ status in breast cancer management.

## **Clinical Pearl / High-Yield Fact**
A key point for students to remember is that ER+ breast cancers are more common in postmenopausal women and have a generally better prognosis than ER- cancers, partly because they can be treated with targeted hormonal therapies. The presence of estrogen receptors also influences the decision-making process for adjuvant therapy.

## **Correct Answer:** . Hormonal therapy may be an effective treatment option.